• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Arazlo (tazarotene)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Arazlo (tazarotene)

  • Profile

Profile

Contact Information

Currently Enrolling Trials

    Show More

    General Information

    Arazlo (tazarotene) is a retinoid.

    Arazlo is specifically indicated for the topical treatment of acne vulgaris in patients 9 years of age and older.

    Arazlo is supplied as a cream for topical administration. Apply a thin layer of Arazlo to the affected areas once daily. Avoid the eyes, mouth, paranasal creases, and mucous membranes. If Arazlo gets in or near eyes, rinse thoroughly with water. Wash hands thoroughly after applying Arazlo. 

    Avoid concomitant use with oxidizing agents, such as benzoyl peroxide.  If the concomitant use of Arazlo with oxidizing agents is required, apply each at different times of the day (e.g. one in the morning and the other in the evening). 

    Use effective sunscreens and wear protective clothing while using Arazlo. 

    Clinical Trials

    FDA Approval

    The FDA approval for Arazlo was based on data from two Phase 3 multicenter, randomized, double-blind, vehicle-controlled clinical trials in 1,614 patients with moderate to severe acne.  The efficacy endpoints of success on the  Evaluator’s Global Severity Score (EGSS), absolute change in noninflammatory lesion count, and absolute change in inflammatory lesion count were assessed at Week 12. Success on the EGSS was defined as at least a 2-grade improvement from Baseline and an EGSS score of clear (0) or almost clear (1). In both Phase 3 studies, all primary efficacy endpoints were met with statistical significance.

    In a Phase 2, head-to-head study, Arazlo and Tazorac (tazarotene) Cream 0.1% showed similar treatment success rates and similar reductions in both inflammatory and non-inflammatory lesions over 12 weeks. While there were no significant differences in patient satisfaction or quality of life between the two treatments and both were well-tolerated, there were numerically about double the number of treatment-related adverse events with Tazorac (5.6 percent with Tazorac versus 2.9 percent with Arazlo).

    Side Effects

    Adverse effects associated with the use of Arazlo may include, but are not limited to, the following:

    • application site reactions
    • pain
    • dryness
    • exfoliation
    • erythema
    • pruritus

    Mechanism of Action

    Arazlo (tazarotene) is a retinoid prodrug which is converted to its active form, tazarotenic acid, the carboxylic acid of tazarotene, by deesterification. Tazarotenic acid binds to all three members of the retinoic acid receptor (RAR) family: RARα, RARβ and RARγ, but shows relative selectivity for RARβ, and RARγ and may modify gene expression. The clinical significance of these findings for the treatment of acne vulgaris is unknown.

    Additional Information

    For additional information regarding Arazlo or acne, please visit the Arazlo web page.

     

     

    Approval Date: 2019-12-01
    Company Name: Ortho Dermalogics
    Back to Listings

    Featured Products

    • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

      Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    Featured Stories

    • MAGI East 2023

      MAGI East 2023 Preview: Janssen Reports on Environmental Impact of Trials

    • Complexity-360x240.png

      Phase 3 Trials Significantly Rising in Complexity, Says CSDD

    • Quality Level Scale

      Build Quality into Trials Like You’d Build a House, Says FDA’s BIMO Director

    • DE&I

      Trust-Building, Community Connection Still Essential to DE&I Efforts, Experts Say

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing